Stockscreener 앱 받기
21.37
5.65%
-1.28
전일 마감가:
$22.65
열려 있는:
$22.68
하루 거래량:
211.57K
Relative Volume:
2.05
시가총액:
$267.70M
수익:
-
순이익/손실:
$-31.48M
주가수익비율:
-20.55
EPS:
-1.04
순현금흐름:
$-28.71M
1주 성능:
+7.23%
1개월 성능:
+47.79%
6개월 성능:
+70.41%
1년 성능:
-7.21%
1일 변동 폭
$21.36
$23.71
1주일 범위
$18.85
$23.71
52주 변동 폭
$4.90
$25.97
Forte Biosciences Inc Stock (FBRX) Company Profile
명칭
Forte Biosciences Inc
전화
(310) 618-6994
주소
3060 PEGASUS PARK DRIVE, DALLAS, CA
FBRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
FBRX
Forte Biosciences Inc
|
21.37 | 283.74M | 0 | -31.48M | -28.71M | -1.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Forte Biosciences Inc Stock (FBRX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-25 | 개시 | Evercore ISI | Outperform |
| 2025-08-18 | 개시 | Guggenheim | Buy |
| 2025-01-21 | 개시 | TD Cowen | Buy |
| 2024-04-08 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-09-20 | 업그레이드 | Chardan Capital Markets | Sell → Buy |
| 2021-09-03 | 다운그레이드 | B. Riley Securities | Buy → Neutral |
| 2021-09-03 | 다운그레이드 | Chardan Capital Markets | Buy → Sell |
| 2021-09-03 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2021-09-03 | 다운그레이드 | Truist | Buy → Hold |
| 2021-05-14 | 개시 | B. Riley Securities | Buy |
| 2021-03-26 | 개시 | Citigroup | Buy |
| 2020-08-28 | 업그레이드 | Chardan Capital Markets | Neutral → Buy |
| 2020-08-25 | 개시 | Truist | Buy |
모두보기
Forte Biosciences Inc 주식(FBRX)의 최신 뉴스
Is Forte Biosciences Inc a good long term investment - earlytimes.in
Positive week for Forte Biosciences, Inc. (NASDAQ:FBRX) institutional investors who lost 1.7% over the past year - Yahoo Finance
Federated Hermes Inc. Buys New Shares in Forte Biosciences, Inc. $FBRX - MarketBeat
Stock Traders Purchase High Volume of Forte Biosciences Call Options (NASDAQ:FBRX) - MarketBeat
Celiac Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight - The Manila Times
Forte Biosciences (FBRX) Stock Analysis Report | Financials & Insights - Benzinga
What downside risks could hit Forte Biosciences Inc. (37T) stockJuly 2025 Weekly Recap & Technical Pattern Based Buy Signals - Newser
Recent Research Analysts’ Ratings Changes for Forte Biosciences (FBRX) - Defense World
Forte Biosciences initiated with an Outperform at Evercore ISI - MSN
What analyst consensus implies for Forte Biosciences Inc. (37T) stockWatch List & Trade Opportunity Analysis Reports - Newser
Is Forte Biosciences Inc. stock a top pick in earnings seasonJuly 2025 Update & Trade Opportunity Analysis - Newser
How forex fluctuations impact Forte Biosciences Inc. (37T) stockTrade Ideas & Weekly Hot Stock Watchlists - Newser
Is Forte Biosciences Inc. stock attractive for passive investors2025 Market WrapUp & High Accuracy Trade Signal Alerts - Newser
Forte Biosciences Inc. (FBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
18,856 Shares in Forte Biosciences, Inc. $FBRX Purchased by Envestnet Asset Management Inc. - MarketBeat
Forte Biosciences, Inc. (FBRX) Analyst insights, Price targets and Recommendations - Yahoo Finance UK
Forte Biosciences (NASDAQ:FBRX) Coverage Initiated by Analysts at Evercore ISI - MarketBeat
Forte Biosciences (NASDAQ:FBRX) Earns Outperform Rating from Analysts at Evercore ISI - Defense World
Forte Biosciences Target of Unusually High Options Trading (NASDAQ:FBRX) - MarketBeat
Analysts Set Forte Biosciences, Inc. (NASDAQ:FBRX) PT at $67.00 - Defense World
Why Forte Biosciences Inc. stock could benefit from AI revolution2025 Year in Review & AI Enhanced Market Trend Forecasts - BỘ NỘI VỤ
How does Forte Biosciences Inc (FBRX) change from a tortoise to a hare? - Setenews
Forte Biosciences, Inc. (NASDAQ:FBRX) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Evercore ISI initiates coverage on Forte Biosciences stock with Outperform rating - Investing.com Australia
Vitiligo Pipeline Advancements Report 2025: DelveInsight Highlights Emerging Therapeutics Reshaping the Treatment Landscape - The Globe and Mail
FBRX: Evercore ISI Group Initiates Coverage with Outperform Rati - GuruFocus
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - marketscreener.com
Forte Biosciences (NASDAQ: FBRX) approves Nasdaq Rule 5635(c)(4) inducement option grant - Stock Titan
What analysts say about Forte Biosciences Inc stockVolume Spike Alerts & Affordable Market Trading - earlytimes.in
Why Forte Biosciences Inc. (37T) stock is a strong buy callQuarterly Earnings Report & Technical Pattern Recognition Alerts - newser.com
What is Chardan Capital’s Estimate for FBRX FY2025 Earnings? - Defense World
Why Forte Biosciences Inc. (37T) stock appears on watchlists2025 Support & Resistance & Safe Entry Zone Tips - newser.com
Will Forte Biosciences Inc. stock gain from lower inflationJuly 2025 Intraday Action & AI Driven Stock Movement Reports - newser.com
Can Forte Biosciences Inc. (37T) stock deliver strong annual returnsJuly 2025 Setups & Low Risk Profit Maximizing Plans - newser.com
Is Forte Biosciences Inc. (37T) stock vulnerable to rate hikes2025 Price Targets & Safe Entry Momentum Stock Tips - newser.com
Will Forte Biosciences Inc. (37T) stock profit from AI boomJuly 2025 Spike Watch & Free Reliable Trade Execution Plans - newser.com
Published on: 2025-11-19 14:11:29 - newser.com
What drives Forte Biosciences Inc stock priceMid Cap Growth Trends & Budget Friendly Growth Tips - earlytimes.in
Why Forte Biosciences Inc. stock is in analyst buy zoneMarket Risk Summary & Technical Buy Zone Confirmations - newser.com
Developing predictive dashboards with Forte Biosciences Inc. data2025 Volume Leaders & Weekly Return Optimization Alerts - newser.com
Forte Biosciences Inc (FBRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.08%
0.91%
자본화:
|
볼륨(24시간):